{"id":"bortezomib-b","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Peripheral neuropathy"},{"rate":"20-40","effect":"Thrombocytopenia"},{"rate":"15-30","effect":"Neutropenia"},{"rate":"20-30","effect":"Anemia"},{"rate":"25-35","effect":"Nausea"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"20-30","effect":"Fatigue"},{"rate":"5-15","effect":"Herpes zoster reactivation"}]},"_chembl":{"chemblId":"CHEMBL325041","moleculeType":"Small molecule","molecularWeight":"384.25"},"_dailymed":{"setId":"cd698074-da21-4b53-8f6b-241535a8d598","title":"BORTEZOMIB INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [GLAND PHARMA LIMITED]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bortezomib is a reversible proteasome inhibitor that blocks the degradation of ubiquitinated proteins, causing accumulation of pro-apoptotic factors and cell cycle inhibitors. This leads to G2/M phase arrest and triggers apoptosis in cancer cells, particularly in multiple myeloma and mantle cell lymphoma. The drug is especially effective in hematologic malignancies where proteasome inhibition disrupts the balance of survival and death signals.","oneSentence":"Bortezomib inhibits the 26S proteasome, preventing the degradation of proteins that regulate cell cycle and apoptosis, leading to cancer cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:21:28.449Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (newly diagnosed and relapsed/refractory)"},{"name":"Mantle cell lymphoma"},{"name":"Light chain myeloma"}]},"trialDetails":[{"nctId":"NCT01861314","phase":"PHASE1","title":"Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-03","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Adult Acute Myeloid Leukemia","enrollment":15},{"nctId":"NCT01695941","phase":"PHASE1","title":"Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-08-31","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma","enrollment":24},{"nctId":"NCT01453088","phase":"PHASE2","title":"Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2010-06-24","conditions":"Multiple Myeloma","enrollment":63},{"nctId":"NCT04268498","phase":"PHASE2","title":"A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-02-11","conditions":"Multiple Myeloma","enrollment":310},{"nctId":"NCT06152575","phase":"PHASE3","title":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-02-08","conditions":"Multiple Myeloma","enrollment":492},{"nctId":"NCT02773030","phase":"PHASE1, PHASE2","title":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2016-10-14","conditions":"Multiple Myeloma","enrollment":466},{"nctId":"NCT07222761","phase":"PHASE3","title":"A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-01-02","conditions":"Relapsed and/or Refractory Multiple Myeloma (RRMM)","enrollment":915},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT05083169","phase":"PHASE3","title":"A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-14","conditions":"Multiple Myeloma","enrollment":587},{"nctId":"NCT03590171","phase":"PHASE2","title":"International Study for Treatment of High Risk Childhood Relapsed ALL 2010","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2017-09-01","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":250},{"nctId":"NCT05257083","phase":"PHASE3","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-10-10","conditions":"Multiple Myeloma","enrollment":759},{"nctId":"NCT04133636","phase":"PHASE2","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-07","conditions":"Multiple Myeloma","enrollment":210},{"nctId":"NCT04181827","phase":"PHASE3","title":"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-06-12","conditions":"Multiple Myeloma","enrollment":419},{"nctId":"NCT04722146","phase":"PHASE1","title":"A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-12","conditions":"Multiple Myeloma","enrollment":140},{"nctId":"NCT06208150","phase":"PHASE3","title":"A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-01-22","conditions":"Multiple Myeloma","enrollment":795},{"nctId":"NCT06577025","phase":"PHASE2","title":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-08-20","conditions":"Multiple Myeloma","enrollment":43},{"nctId":"NCT07149857","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-10-03","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT04923893","phase":"PHASE3","title":"A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-19","conditions":"Multiple Myeloma","enrollment":743},{"nctId":"NCT07391657","phase":"PHASE3","title":"A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-02-23","conditions":"Relapsed Refractory Multiple Myeloma","enrollment":508},{"nctId":"NCT04151667","phase":"PHASE2","title":"Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-11-22","conditions":"Multiple Myeloma","enrollment":33},{"nctId":"NCT06083922","phase":"PHASE2","title":"A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-10-16","conditions":"Multiple Myeloma, Monoclonal Gammopathy of Renal Significance","enrollment":20},{"nctId":"NCT04566328","phase":"PHASE3","title":"Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-24","conditions":"Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma","enrollment":1450},{"nctId":"NCT05804032","phase":"PHASE3","title":"Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"University of Heidelberg Medical Center","startDate":"2023-04-14","conditions":"Multiple Myeloma","enrollment":514},{"nctId":"NCT03710603","phase":"PHASE3","title":"Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2018-12-14","conditions":"Multiple Myeloma","enrollment":709},{"nctId":"NCT04285268","phase":"PHASE2","title":"Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"WITHDRAWN","sponsor":"Rutgers, The State University of New Jersey","startDate":"2020-05-06","conditions":"High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT05137054","phase":"PHASE1","title":"A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-17","conditions":"Multiple Myeloma","enrollment":317},{"nctId":"NCT05250973","phase":"PHASE2","title":"A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-03-01","conditions":"Amyloidosis","enrollment":151},{"nctId":"NCT07341867","phase":"PHASE1","title":"Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype","status":"NOT_YET_RECRUITING","sponsor":"Andrew Hantel, MD","startDate":"2026-06","conditions":"Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation","enrollment":90},{"nctId":"NCT05231629","phase":"PHASE2","title":"Sequential Therapy in Multiple Myeloma Guided by MRD Assessments","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2023-12-13","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT05675319","phase":"PHASE3","title":"Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2023-03-03","conditions":"Multiple Myeloma","enrollment":28},{"nctId":"NCT04991103","phase":"PHASE2","title":"Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-22","conditions":"Multiple Myeloma, Amyloidosis","enrollment":40},{"nctId":"NCT07072585","phase":"PHASE2, PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma","enrollment":1708},{"nctId":"NCT05695508","phase":"PHASE2","title":"GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5","status":"RECRUITING","sponsor":"University of Heidelberg Medical Center","startDate":"2022-12-01","conditions":"Multiple Myeloma","enrollment":160},{"nctId":"NCT04653246","phase":"PHASE2","title":"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jacob Laubach, MD","startDate":"2021-07-13","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant","enrollment":52},{"nctId":"NCT07285239","phase":"PHASE3","title":"Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"PrECOG, LLC.","startDate":"2026-05","conditions":"Multiple Myeloma","enrollment":500},{"nctId":"NCT03620903","phase":"PHASE2","title":"Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Christian Buske","startDate":"2019-09-11","conditions":"Waldenstrom Macroglobulinemia","enrollment":53},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT03829371","phase":"PHASE4","title":"STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Turin, Italy","startDate":"2019-01-03","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT02112916","phase":"PHASE3","title":"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-04","conditions":"Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma","enrollment":847},{"nctId":"NCT01371981","phase":"PHASE3","title":"Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Acute Myeloid Leukemia, Leukemia Cutis, Myeloid Neoplasm","enrollment":1645},{"nctId":"NCT01286272","phase":"PHASE2","title":"Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-04-28","conditions":"Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma","enrollment":135},{"nctId":"NCT00310037","phase":"PHASE2","title":"Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2006-06","conditions":"Mantle Cell Lymphoma","enrollment":151},{"nctId":"NCT05564052","phase":"PHASE2","title":"A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2022-12-06","conditions":"Lymphoma, Mantle-Cell","enrollment":36},{"nctId":"NCT01863550","phase":"PHASE3","title":"Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2013-12-06","conditions":"Plasma Cell Myeloma","enrollment":1087},{"nctId":"NCT01415882","phase":"PHASE2","title":"Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-01-31","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":165},{"nctId":"NCT02195479","phase":"PHASE3","title":"A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-12-09","conditions":"Multiple Myeloma","enrollment":706},{"nctId":"NCT07085728","phase":"PHASE2","title":"Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure","status":"NOT_YET_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2025-08-11","conditions":"Myeloma Multiple","enrollment":74},{"nctId":"NCT03828292","phase":"PHASE1","title":"An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-03-14","conditions":"Multiple Myeloma","enrollment":15},{"nctId":"NCT03314181","phase":"PHASE2","title":"A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2018-04-02","conditions":"Multiple Myeloma","enrollment":156},{"nctId":"NCT07045909","phase":"PHASE2","title":"Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)","status":"RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2025-06-30","conditions":"De Novo Multiple Myeloma, Anitocabtagene Autoleucel","enrollment":30},{"nctId":"NCT06918002","phase":"PHASE3","title":"Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients","status":"RECRUITING","sponsor":"Intergroupe Francophone du Myelome","startDate":"2025-07-09","conditions":"Multiple Myeloma, Newly Diagnosed","enrollment":824},{"nctId":"NCT07051850","phase":"","title":"Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies","status":"RECRUITING","sponsor":"Sung-Soo Park","startDate":"2025-07-14","conditions":"Multiple Myeloma, Relapsed, Multiple Myeloma (MM)","enrollment":174},{"nctId":"NCT04775550","phase":"PHASE2","title":"DARA RVD For High Risk SMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Omar Nadeem, MD","startDate":"2021-03-08","conditions":"High-risk Smoldering Multiple Myeloma, Multiple Myeloma","enrollment":61},{"nctId":"NCT00734877","phase":"PHASE3","title":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":382},{"nctId":"NCT06956170","phase":"PHASE3","title":"All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-02-10","conditions":"Multiple Myeloma","enrollment":21},{"nctId":"NCT06868667","phase":"PHASE3","title":"Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2021-07-28","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT06868654","phase":"PHASE3","title":"China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2021-07-28","conditions":"Multiple Myeloma","enrollment":72},{"nctId":"NCT02541383","phase":"PHASE3","title":"A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Intergroupe Francophone du Myelome","startDate":"2015-09","conditions":"Multiple Myeloma","enrollment":1085},{"nctId":"NCT01415752","phase":"PHASE2","title":"Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2012-08-09","conditions":"Lymphoma, Mantle Cell Lymphoma","enrollment":373},{"nctId":"NCT06900647","phase":"PHASE1","title":"Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-01-01","conditions":"Metastatic Breast Cancer, Recurrent Breast Cancer","enrollment":20},{"nctId":"NCT03544281","phase":"PHASE1, PHASE2","title":"To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-09-20","conditions":"Multiple Myeloma","enrollment":153},{"nctId":"NCT04484623","phase":"PHASE3","title":"Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2020-10-01","conditions":"Multiple Myeloma","enrollment":302},{"nctId":"NCT04717700","phase":"PHASE2","title":"Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ida Bruun Kristensen","startDate":"2021-08-18","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT04304144","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-03-18","conditions":"AL Amyloidosis","enrollment":25},{"nctId":"NCT06796517","phase":"","title":"Immunotherapy in Lymphoma","status":"RECRUITING","sponsor":"Sung-Soo Park","startDate":"2024-06-26","conditions":"Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma Relapsed","enrollment":72},{"nctId":"NCT03129828","phase":"PHASE1, PHASE2","title":"Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2","status":"COMPLETED","sponsor":"Prof. Dr. Clemens Schmitt","startDate":"2017-03-17","conditions":"Diffuse Large B Cell Lymphoma","enrollment":38},{"nctId":"NCT05665140","phase":"PHASE2, PHASE3","title":"Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"University Hopsital Schleswig Holstein Campus Lübeck","startDate":"2023-02-03","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":100},{"nctId":"NCT02057380","phase":"PHASE2","title":"A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2014-04-16","conditions":"Advanced Solid Tumors","enrollment":13},{"nctId":"NCT04246047","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2020-05-07","conditions":"Multiple Myeloma","enrollment":494},{"nctId":"NCT01183949","phase":"PHASE1, PHASE2","title":"Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2010-11","conditions":"Multiple Myeloma","enrollment":18},{"nctId":"NCT02654990","phase":"PHASE2","title":"Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2016-04-27","conditions":"Multiple Myeloma","enrollment":248},{"nctId":"NCT03234972","phase":"PHASE3","title":"A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-30","conditions":"Multiple Myeloma","enrollment":213},{"nctId":"NCT03188172","phase":"PHASE2","title":"MUK Nine b: OPTIMUM Treatment Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Leeds","startDate":"2017-09-28","conditions":"Multiple Myeloma","enrollment":95},{"nctId":"NCT01788020","phase":"PHASE3","title":"Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia","status":"COMPLETED","sponsor":"University of Ulm","startDate":"2013-11","conditions":"Waldenström's Macroglobulinemia","enrollment":202},{"nctId":"NCT03217812","phase":"PHASE3","title":"A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-23","conditions":"Multiple Myeloma","enrollment":220},{"nctId":"NCT01063907","phase":"PHASE1, PHASE2","title":"A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-03","conditions":"Multiple Myeloma","enrollment":95},{"nctId":"NCT00863369","phase":"PHASE1, PHASE2","title":"Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2005-06-29","conditions":"Lymphoma","enrollment":33},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT02513186","phase":"PHASE1","title":"Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-09-30","conditions":"Plasma Cell Myeloma","enrollment":90},{"nctId":"NCT01142401","phase":"PHASE2","title":"Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-05-26","conditions":"Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7","enrollment":118},{"nctId":"NCT02188368","phase":"PHASE2","title":"Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients","status":"TERMINATED","sponsor":"Oncotherapeutics","startDate":"2014-07-07","conditions":"Multiple Myeloma","enrollment":45},{"nctId":"NCT00571493","phase":"PHASE1, PHASE2","title":"VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2006-04-14","conditions":"Non-hodgkin's Lymphoma, Mantle Cell Lymphoma","enrollment":42},{"nctId":"NCT05982756","phase":"PHASE1","title":"Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML","status":"UNKNOWN","sponsor":"Zhongnan Hospital","startDate":"2020-01-01","conditions":"Bortezomib, Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT01216683","phase":"PHASE2","title":"Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2011-02-09","conditions":"Lymphoma","enrollment":289},{"nctId":"NCT03001804","phase":"","title":"Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-06-30","conditions":"Multiple Myeloma","enrollment":29},{"nctId":"NCT01685814","phase":"PHASE3","title":"Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance","status":"UNKNOWN","sponsor":"Wuerzburg University Hospital","startDate":"2012-05","conditions":"Previously Untreated Symptomatic Multiple Myeloma","enrollment":406},{"nctId":"NCT01420926","phase":"PHASE2","title":"Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-11-16","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Therapy-Related Acute Myeloid Leukemia","enrollment":165},{"nctId":"NCT03481556","phase":"PHASE1, PHASE2","title":"Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM","status":"TERMINATED","sponsor":"Oncopeptides AB","startDate":"2018-04-12","conditions":"Multiple Myeloma","enrollment":56},{"nctId":"NCT03651128","phase":"PHASE3","title":"Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":381},{"nctId":"NCT00114738","phase":"PHASE2","title":"EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2005-06-15","conditions":"Lymphoma, Mantle Cell, Mantle Cell Lymphoma","enrollment":53},{"nctId":"NCT05558319","phase":"PHASE3","title":"NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide","status":"NOT_YET_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2022-10","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":480},{"nctId":"NCT00464178","phase":"PHASE2","title":"A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Hackensack Meridian Health","startDate":"2007-04","conditions":"Multiple Myeloma","enrollment":7},{"nctId":"NCT01805557","phase":"PHASE2, PHASE3","title":"Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2013-02-04","conditions":"Diffuse Large B-cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent","enrollment":108},{"nctId":"NCT01078454","phase":"PHASE3","title":"Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-11","conditions":"Light Chain Deposition Disease, Primary Systemic Amyloidosis","enrollment":11},{"nctId":"NCT02424851","phase":"PHASE2","title":"Optimising Renal Outcome in Myeloma Renal Failure","status":"COMPLETED","sponsor":"Oxford University Hospitals NHS Trust","startDate":"2014-11","conditions":"Multiple Myeloma, Chronic Kidney Disease","enrollment":31},{"nctId":"NCT02703779","phase":"PHASE2","title":"Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)","status":"COMPLETED","sponsor":"Siddhartha Ganguly","startDate":"2016-03","conditions":"Multiple Myeloma","enrollment":101},{"nctId":"NCT00702052","phase":"PHASE2","title":"Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-08-22","conditions":"Lymphoma, Mantle- Cell","enrollment":58},{"nctId":"NCT02037256","phase":"NA","title":"Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2011-07","conditions":"Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma","enrollment":23},{"nctId":"NCT01125293","phase":"PHASE1, PHASE2","title":"Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2010-04","conditions":"Waldenstrom's Macroglobulinemia","enrollment":46},{"nctId":"NCT01088048","phase":"PHASE1","title":"Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-03-25","conditions":"Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma","enrollment":241}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Velcade"],"phase":"marketed","status":"active","brandName":"Bortezomib (B)","genericName":"Bortezomib (B)","companyName":"National Cancer Institute (NCI)","companyId":"national-cancer-institute-nci","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bortezomib inhibits the 26S proteasome, preventing the degradation of proteins that regulate cell cycle and apoptosis, leading to cancer cell death. Used for Multiple myeloma (newly diagnosed and relapsed/refractory), Mantle cell lymphoma, Light chain myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}